Skip to content
The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. But it is struggling with more than 2,500 lawsuits over its opioid sales and other issues. About Us The Fool has written over 100 articles on Mallinckrodt.
Get the latest Mallinckrodt plc (MNK) stock news and headlines to help you in your trading and investing decisions. Disruptions and high demand have expanded concerns about the supply of medicines.Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mallinckrodt (MNK), BioMarin Pharmaceutical (BMRN) and Cocrystal Pharma ...[...]DOJ wants as much as $18.1B From Purdue Pharma for opioid epidemicThe drugmaker said it may have to file for chapter 11 protection after an unfavorable court ruling surrounding the multiple-sclerosis drug Acthar.Mallinckrodt plc (MNK) CEO Mark Trudeau on Q2 2020 Results - Earnings Call TranscriptMallinckrodt (MNK) delivered earnings and revenue surprises of 51.20% and 12.56%, respectively, for the quarter ended June 2020. It operates through the Specialty Brands and Specialty Generics segments. View which stocks are hot on social media with MarketBeat's trending stocks report.Identify stocks that meet your criteria using seven unique stock screeners. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin. Real time Mallinckrodt (MNK) stock price quote, stock graph, news & analysis. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Get daily stock ideas top-performing Wall Street analysts. Stock Market Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Mallinckrodt against related stocks people have also bought. Mallinckrodt Plc is a global specialty pharmaceuticals company. Want to see which stocks are moving? All rights reserved. Disruptions and high demand have expanded concerns about the supply of medicines.The drugmaker said it may have to file for chapter 11 protection after an unfavorable court ruling surrounding the multiple-sclerosis drug Acthar.Thursday's top analyst upgrades and downgrades included Costco, Enphase Energy, Etsy, Moderna, Novavax, Regeneron Pharmaceuticals, Roku, Square, Teva Pharmaceutical, Wayfair and Zynga.Corrections & Amplifications for the edition of Aug. 6, 2020.Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter. With a one year PEG ratio of 0.14, Mallinckrodt plc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 3.08% of US stocks. Retirement Please log in to your account or sign up in order to add this asset to your watchlist. View the real-time MNK price chart on Robinhood and decide if you want to buy or sell commission-free. MNK | Complete Mallinckrodt PLC stock news by MarketWatch. Shares of Mallinckrodt PLC plunged 25% in premrket trading Tuesday, reversing an earlier gain, after the specialty pharmaceutical company swung to a large net loss, but reported an adjusted profit that beat expectations, while disclosing talks with creditors and litigation claimants regarding the possibility of a bankruptcy filing. And it had some other big news that overshadowed its Q4 performance.Investors are cheering the company's deal to settle opioid-related lawsuits.Shares fell by as much as 45% in light of the news.Investors were disappointed by the company's Q1 results and the prospects of continued challenges from the COVID-19 pandemic.Investors are cheering the company's deal to settle opioid-related lawsuits.Momentum from its CEO's comments earlier this week continues.Investors appear to be optimistic about the drugmaker's impending Q3 update.Investors continue to grapple with the uncertainty hanging over the company.The company is reportedly considering bankruptcy to cope with its financial exposure in the opioid crisis.Worries about opioid litigation and a recent patent lawsuit loss continue to weigh on the drugmaker.Investors appear to have some confidence that the companies will settle their opioid lawsuits.Positive clinical-trial results couldn't save the embroiled biotech.MNK earnings call for the period ending March 31, 2020.MNK earnings call for the period ending December 31, 2019.MNK earnings call for the period ending June 30, 2019.MNK earnings call for the period ending March 31, 2019.MNK earnings call for the period ending December 28, 2018.MNK earnings call for the period ending September 30, 2018. Do the numbers hold clues to what lies ahead for the stock?Mallinckrodt down 20% on talks of possible bankruptcy filingMallinckrodt plummets 20% on talks of possible bankruptcy filingMallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.